Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy-Reference-Cited by-同舟云学术

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy

Published:2019-05-17 Issue:7 Volume:85 Page:1495-1506
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Jamois Candice¹^ORCID,Gibiansky Ekaterina²,Gibiansky Leonid²,Buchheit Vincent¹,Sahin Denis³,Cartron Guillaume⁴,Marcus Robert⁵,Hiddemann Wolfgang⁶,Seymour John F.⁷,Strefford Jonathan C.⁸^ORCID,Hargreaves Chantal E.⁸,Meneses‐Lorente Georgina³,Frey Nicolas¹,Fingerle‐Rowson Günter⁹

Affiliation:

1. Department of Clinical PharmacologyF. Hoffmann–La Roche, Roche Innovation Center Basel Switzerland

2. QuantPharm LLC North Potomac MD USA

3. Roche Innovation Center Welwyn UK

4. Department of HematologyCHU Montpellier Montpellier France

5. Kings College Hospital London UK

6. Department of Medicine IIIUniversity Hospital, LMU Munich Germany

7. Peter MacCallum Cancer CentreRoyal Melbourne Hospital and University of Melbourne Melbourne Australia

8. Cancer Genomics, Cancer Sciences, Faculty of MedicineGroup University of Southampton Southampton UK

9. Pharma Development OncologyF. Hoffmann‐La Roche Basel Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13920

Reference55 articles.

1. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

3. NCCN Clinical Practice Guidelines in Oncology: NHL version 4.2014.https://www.nccn.org/professionals/physician_gls/recently_updated.aspx. Accessed 12 February 2018.

4. Rituxan US Label.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf. Accessed 27 November 2017.

5. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group;International Journal of Hematology;2022-05-18

2. Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia;CPT: Pharmacometrics & Systems Pharmacology;2021-07-16

3. Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies;Clinical Pharmacology & Therapeutics;2021-06-26

4. Sex as decisive variable in lymphoid neoplasms—an update;ESMO Open;2021-02

5. Anti-CD20 treatment for B-cell malignancies: current status and future directions;Expert Opinion on Biological Therapy;2020-11-09